Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study
β Scribed by T. Witthoeft; D. Hueppe; C. John; J. Goelz; R. Heyne; B. Moeller; G. Teuber; S. Wollschlaeger; A. Baumgarten; K.-G. Simon; G. Moog; N. Dikopoulos; S. Mauss
- Book ID
- 108886404
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 153 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1352-0504
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40 KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis
Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, placebo-controlled trial in 19 Spanish hospitals, including 12
Chronic hepatitis C virus (HCV) infection is usually asymptomatic in children, but significant liver disease may occur. We evaluated the efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic HCV. We determined the optimal ribavirin dose in an initial coh